NCT04785833 - CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

April 30, 2022

Study Completion Date

February 4, 2024

Conditions

T-ALL

Interventions

DRUG

T cell injection targeting CD7 chimeric antigen receptor

Drug name: T cell injection targeting CD7 autologous chimeric antigen receptor. Package specification: 10-50ml bag, 1-4 bags / person, which is determined according to the body weight of the subject and the effective content of cell preparation

Trial Locations (1)

215006

RECRUITING

The First Affiliared Hospital Of SOOCHOW University, Suzhou